CoChat

Targeted clearance of senescent cells using an antibody-drug conjugate against a specific membrane marker

Open access

The DOI matches its Crossref record; 77 of the 77 references it cites were found in a registry or an index.

Abstract

A wide range of diseases have been shown to be influenced by the accumulation of senescent cells, from fibrosis to diabetes, cancer, Alzheimer’s and other age-related pathologies. Consistent with this, clearance of senescent cells can prolong healthspan and lifespan in in vivo models. This provided a rationale for developing a new class of drugs, called senolytics, designed to selectively eliminate senescent cells in human tissues. The senolytics tested so far lack specificity and have significant off-target effects, suggesting that a targeted approach could be more clinically relevant. Here, we propose to use an extracellular epitope of B2M, a recently identified membrane marker of senescence, as a target for the specific delivery of toxic drugs into senescent cells. We show that an antibody–drug conjugate (ADC) against B2M clears senescent cells by releasing duocarmycin into them, while an isotype control ADC was not toxic for these cells. This effect was dependent on p53 expression and therefore more evident in stress-induced senescence. Non-senescent cells were not affected by either antibody, confirming the specificity of the treatment. Our results provide a proof-of-principle assessment of a novel approach for the specific elimination of senescent cells using a second generation targeted senolytic against proteins of their surfaceome, which could have clinical applications in pathological ageing and associated diseases.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41598-021-99852-2

Cites

77 of 77 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 B2M expression increases with age in mice. (A) Representative images of immunohistochemical staining (left) of skin and brain (frontal lobe) samples from mice of different ages (3–87 weeks), showing B2M expression, as compared to p16 (senescence marker) Magnification: × 20. Graphs show quantitation of expression as %DAB (right). Bars represent the average of three independent samples for skin and five for brain, error bars represent standard deviation (SD). Fold change quantifications of B2M protein (B) and mRNA (C) expression levels, as measured by Western blot and quantitative real-time PCR, respectively, in EJp53, EJp21, EJp16 and HT1080-p21-9 cells induced to senesce for 4 days, normalized to the expression of their proliferating counterparts (represented by the dotted line at y = 1). Bars represent the mean ± SD of 3 independent experiments. ** p < 0.005 (compared to proliferating controls).
Figure 1 B2M expression increases with age in mice. (A) Representative images of immunohistochemical staining (left) of skin and brain (frontal lobe) samples from mice of different ages (3–87 weeks), showing B2M expression, as compared to p16 (senescence marker) Magnification: × 20. Graphs show quantitation of expression as %DAB (right). Bars represent the average of three independent samples for skin and five for brain, error bars represent standard deviation (SD). Fold change quantifications of B2M protein (B) and mRNA (C) expression levels, as measured by Western blot and quantitative real-time PCR, respectively, in EJp53, EJp21, EJp16 and HT1080-p21-9 cells induced to senesce for 4 days, normalized to the expression of their proliferating counterparts (represented by the dotted line at y = 1). Bars represent the mean ± SD of 3 independent experiments. ** p < 0.005 (compared to proliferating controls).CC BY · PubMed Central
Figure 2 Characteristics of B2M-ADCs. (A) Internalization rate of the unconjugated B2M antibody in Control EJp16 cells as measured by CypHer5E fluorescence in a FACS analysis. Results show mean ± SD of three independent experiments. Results show mean ± SD of three independent experiments. (B) Size-Exclusion Chromatography characterization of the purity of the final ADC mix, compared to pure antibody and PBS. (C) SDS page comparing 1 µg of the unconjugated B2M antibody (UC) to an aliquot of the B2M ADC. (D) Quantitation of Drug-Antibody Ratios (DAR) of the B2M conjugated antibodies. Numbers indicate percentages of each DAR population in the mixture. Average DAR: 2.02.
Figure 2 Characteristics of B2M-ADCs. (A) Internalization rate of the unconjugated B2M antibody in Control EJp16 cells as measured by CypHer5E fluorescence in a FACS analysis. Results show mean ± SD of three independent experiments. Results show mean ± SD of three independent experiments. (B) Size-Exclusion Chromatography characterization of the purity of the final ADC mix, compared to pure antibody and PBS. (C) SDS page comparing 1 µg of the unconjugated B2M antibody (UC) to an aliquot of the B2M ADC. (D) Quantitation of Drug-Antibody Ratios (DAR) of the B2M conjugated antibodies. Numbers indicate percentages of each DAR population in the mixture. Average DAR: 2.02.CC BY · PubMed Central
Figure 3 A B2M-duocarmycin ADC selectively kills senescent cells. (A) Representative Western Blot of B2M expression in EJp53, EJp21, EJp16 and HT1080-p21-9 cells 4 days after induction of p53 or p16 respectively, compared to EJp53 cells transfected with B2M cDNA for 4 days (+ B) . (B) Western blot showing B2M expression for different periods of time (0–6 days) in EJp53 cells transfected with B2M cDNA. (C–D) Cell viability, as measured by Cell Titre Glo, of proliferating and senescent (4 days after induction) EJp53 and EJp16 cells, incubated with different concentrations (C) or only 0.05 μM (bottom) of the B2M ADC or an isotype control for 72 h. An EJp53 cell transfected with B2M for 4 days was used as a positive control (+ B). Line and bar charts show the mean of 4 independent experiments. Colour codes match all panels. Bar represent the mean ± SD. * p < 0.05, ** p < 0.005. (E) Cell death, as measured by PI staining, in the same cells as above. Graphs show percentage of PI positive cells (dead cells). Bars represent the mean ± SD. * p < 0.05, ** p < 0.005.
Figure 3 A B2M-duocarmycin ADC selectively kills senescent cells. (A) Representative Western Blot of B2M expression in EJp53, EJp21, EJp16 and HT1080-p21-9 cells 4 days after induction of p53 or p16 respectively, compared to EJp53 cells transfected with B2M cDNA for 4 days (+ B) . (B) Western blot showing B2M expression for different periods of time (0–6 days) in EJp53 cells transfected with B2M cDNA. (C–D) Cell viability, as measured by Cell Titre Glo, of proliferating and senescent (4 days after induction) EJp53 and EJp16 cells, incubated with different concentrations (C) or only 0.05 μM (bottom) of the B2M ADC or an isotype control for 72 h. An EJp53 cell transfected with B2M for 4 days was used as a positive control (+ B). Line and bar charts show the mean of 4 independent experiments. Colour codes match all panels. Bar represent the mean ± SD. * p < 0.05, ** p < 0.005. (E) Cell death, as measured by PI staining, in the same cells as above. Graphs show percentage of PI positive cells (dead cells). Bars represent the mean ± SD. * p < 0.05, ** p < 0.005.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 77 references

Cited by

See all 146

Metadata

Authors
Poblocka, M., Bassey, A. L., Smith, V. M., Falcicchio, M., Manso, A. S., Althubiti, M., Sheng, X., Kyle, A., Barber, R., Frigerio, M., & Macip, S.
Affiliations
  • University of Leicester (GB)
  • Abzena (United Kingdom) (GB)
  • Universitat Oberta de Catalunya (ES)
Corresponding author
Macip, Salvador
Venue
Scientific Reports
Published
2021-10-13
Volume
11
Issue
1
Pages
20358-20358
ISSN
2045-2322 (ISSN-L)
OpenAlex
W3207332839
Cited by
137
References
77
Citations by year
2026: 17 · 2025: 38 · 2024: 39 · 2023: 24 · 2022: 19
FWCI
12.88
Type
journal article
Language
en
Open access
Licence
Locations
  • Scientific Reports (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • The Oberta in Open Access (Universitat Oberta de Catalunya) (submittedVersion, cc-by)
Funders
BBSRC
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Telomeres, Telomerase, and Senescence
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Aging › Genetics, Aging, and Longevity in Model Organisms
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
Keywords
senolytics, senescent cells, antibody-drug conjugates, beta2-microglobulin, duocarmycin, p53, stress-induced senescence, extracellular epitope, pathological aging, healthspan
MeSH terms
Duocarmycins, Senotherapeutics, beta 2-Microglobulin, Cell Line, Gene Expression Regulation, Humans, Tumor Suppressor Protein p53, Cellular Senescence, Immunoconjugates

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Targeted clearance of senescent cells using an antibody-drug conjugate against a specific membrane marker. https://app.cochat.ai/papers/10.1038/s41598-021-99852-2
The paper
Poblocka, M., Bassey, A. L., Smith, V. M., Falcicchio, M., Manso, A. S., Althubiti, M., Sheng, X., Kyle, A., Barber, R., Frigerio, M., & Macip, S. (2021). Targeted clearance of senescent cells using an antibody-drug conjugate against a specific membrane marker. Scientific Reports. https://doi.org/10.1038/s41598-021-99852-2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.